Payers recognize the long-term cost offsets of early metabolic intervention, prompting broader benefit coverage across employer and commercial plans
Clinical Perspective "GLP-1 medications can offer real short-term benefits in terms of appetite reduction and early weight loss, but it is important to have realistic expectations about what happens when stopping GLP-1 medication," says Alessandro Grenci, Superintendent Pharmacist at Medino
2007;293:R9837
In conclusion, in the treatment process of improving sarcopenia with GLP-1RAs, clinicians should formulate individualized plans, closely monitor the patients weight, nutritional intake and changes in body composition, and regularly assess muscle mass using tools such as ultrasound and bioelectrical impedance analysis, so as to adjust the plan in a timely manner [70, 71]
This process involves the activation of integrins and other mechanosensitive proteins, which transmit mechanical stimuli to the cytoskeleton, triggering signaling cascades such as the MAPK/ERK pathway
